Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
11/02/2022* -- Results Q3 2022 -- 0.72 --
11/02/2022* 08:00 EST Earnings Call Q3 2022 -- -- --
08/02/2022 -- Results Q2 2022 1.01 0.75 35.50%
08/02/2022 08:00 EST Earnings Call Q2 2022 -- -- --
05/03/2022 -- Results Q1 2022 0.55 0.69 -20.06%
05/03/2022 08:00 EST Earnings Call Q1 2022 -- -- --
02/08/2022 -- Results Q4 2021 0.10 0.87 -88.45%
02/08/2022 08:00 EST Earnings Call Q4 2021 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 11/02/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade

Loading chart...
Last Report Date 08/02/2022
Beat/Miss Upgrade
Return Since -6.78%
Last FQE 06/30/2022
Next FQE 09/30/2022

Profile

Edit
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
URL https://www.incyte.com
Investor Relations URL https://investor.incyte.com/
HQ State/Province Delaware
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Dividends

Dividend Per Share (TTM) --
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 0.00
Yield to Sector 0.00
Yield to Industry 0.00
Last Dividend Amt. --
Dividend Frequency --
Last Ex-Dividend Date --
Yield (TTM) 0%
Forward Yield --
Payout Ratio 0.00%
Cash Payout Ratio 0.00%
Consistent Payer (5Y) No
Consistent Growth (5Y) No

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
48.34%
-7.54%
-5.54%
-32.86%
37.32%
-0.39%
-15.61%
-7.82%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-21.05%
25.37%
-10.37%
17.83%
40.45%
16.15%
31.06%
66.08%
22.36%
7.30%
4.68%
16.13%
25.06%
-6.73%
3.51%
66.74%
-22.99%
41.48%
-84.98%
-1.59%
48.39%
-89.18%
2.70K%
28.30%
-86.29%
59.29%
-12.42%
222.6%
-41.84%
-24.64%
19.84%
-50.83%
-5.43%
As of September 28, 2022.

Profile

Edit
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
URL https://www.incyte.com
Investor Relations URL https://investor.incyte.com/
HQ State/Province Delaware
Sector Healthcare
Industry Biotechnology
Equity Style Mid Cap/Growth
Next Earnings Release Nov. 02, 2022 (est.)
Last Earnings Release Aug. 02, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
FBT 37.49M USD 2.93%
ARKG 67.40M USD 2.92%
RBF5407 220.82M USD 2.60%
RBF1370 48.63M USD 2.58%
RBF5477 34.10M USD 2.32%
RBF1045 32.52M USD 2.28%
TDB3016 22.08M USD 1.71%
SPGP 20.55M USD 1.69%
IBB 111.57M USD 1.53%
VGHCX 683.76M USD 1.51%
XBI 68.84M USD 1.04%
XT 19.71M USD 0.73%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership
Nasdaq Option Chain
SEC SEC Filings
Twitter INCY Tweets